Shanghai, China, 5 November 2021 — MicroPort^® CardioFlow Medtech Corporation (02160.HK, MicroPort^® CardioFlow) is set to become the largest shareholder of 4C Medical Technologies, Inc. (4C Medical) following the recent completion of a series C preferred shares subscription agreement. As the lead investor of the round, MicroPort^® CardioFlow will make a strategic investment up to USD 25 million in 4C Medical, and will be granted the exclusive commercial rights to the investigational tricuspid products in China.

Shanghai, China, 30 October 2021 — MicroPort^® CardioFlow Medtech Corporation (MicroPort^® CardioFlow) recently hosted a launch event for the VitaFlow Liberty™ Transcatheter Aortic Valve and Retrievable Delivery System (VitaFlow Liberty™), a next-generation product for transcatheter aortic valve implantation (“TAVI”). The product, presented at China Structural Week 2021 and the 5th China International Structural Heart Disease Conference held in Beijing, Shanghai, Guangzhou, and Xi'an, drew the attention of experts in the field of structural heart disease and triggered discussions on the development of the TAVI procedure.

Shanghai, China—MicroPort^® CardioFlow Medtech Corporation (MicroPort^® CardioFlow) is pleased to announce the results of the Company and its subsidiaries for the year ended December 31st, 2020.